Clinical Trials on Non Small Cell Lung Cancer (Squamous or Non Squamous) in Netherlands

Total 470 results

Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

United States, Netherlands
Hoffmann-La Roche

Completed

An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Netherlands
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Netherlands, United Kingdom
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Non-squamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France, Germany, Spain, Sweden, Russian Federation, Greece, Switzerland, Korea, Republic of, Italy, Netherlands, Turkey, United Arab Emirates
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Australia, France, Germany, Spain, China, Hong Kong, Canada, Sweden, Colombia, Taiwan, United Kingdom, Russian Federation, Finland, Austria, Estonia, Hungary, Netherlands, Latvia, Italy, Mexico, Slovenia, Turkey, Bosnia and Herzegovina and more
Hoffmann-La Roche

Completed

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Austria, Denmark, Italy, Spain, Germany, Mexico, Netherlands, Japan, Brazil, Greece, Argentina, Slovakia, Lebanon, Belgium, Oman, United Arab Emirates
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Squamous Non-Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Brazil, Canada, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, P... and more
Mirati Therapeutics Inc.
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

Metastatic Non-Squamous Non-Small Cell Lung Cancer

United States, Canada, Belgium, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Non-Squamous Non-Small Cell Lung Cancer

China, Korea, Republic of, South Africa, Taiwan, Hungary, France, Netherlands, United States, Bulgaria, Slovakia, Canada, Italy, Brazil, Thailand, Romania, Lithuania, Poland, Latvia, Ukraine, Czech Republic
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Maastricht Radiation Oncology

Completed

Concurrent Chemo-radiation Form NSCLC to a Individualized MLD (BRONC CONC MLD)

Non-small Cell Lung Cancer

Netherlands
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Maastricht Radiation Oncology

Completed

Usefulness of Blood Biomarkers for Overall Survival in NSCLC

Non-small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Radiotherapy for NSCLC to a Individualized MLD (BRONC MLD)

Non-small Cell Lung Cancer

Netherlands
Radboud University Medical Center
AstraZeneca

Completed

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (Donan)

Non-small Cell Lung Cancer

Netherlands
Radboud University Medical Center
Merck KGaA, Darmstadt, Germany

Completed

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (PINNACLE)

Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology
University of Pennsylvania

Completed

State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients (Lung stage I)

Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
The Netherlands Cancer Institute

Completed

Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm. (N12HYB)

Inoperable Locally Advanced Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Withdrawn

DE-CT in Lung Cancer Proton Therapy (DE-CT)

Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Maastro...

Completed

Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients. (Metformin)

Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology
Merck Sharp & Dohme LLC; Academisch Ziekenhuis Maastricht

Completed

Phase I Cetuximab and Concurrent Radio-chemotherapy

Non-small Cell Lung Cancer

Netherlands
Amsterdam UMC, location VUmc
Boehringer Ingelheim

Recruiting

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP)

Advanced Stage Non-small Cell Lung Cancer

Netherlands
Frame Pharmaceuticals B.V.
University Medical Center Groningen; Erasmus Medical Center; The Netherlands... and other collaborators

Not yet recruiting

FRAME-001 Personalized Vaccine in NSCLC

Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)

Stage I-III Non-small Cell Lung Cancer

Netherlands
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC

Unknown

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Non Small Cell Lung Cancer

Netherlands
Radboud University Medical Center

Terminated

Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy (IDEAL-VMAT)

Stage III Non-small Cell Lung Cancer | Individualized Radiation Dose Escalation

Netherlands
UMC Utrecht

Unknown

MRI Optimization Study in Stage III NSCLC

Stage III Non-small Cell Lung Cancer

Netherlands
Erasmus Medical Center

Recruiting

TEIPP Immunotherapy in Patients With NSCLC (TEIPP)

Non Small Cell Lung Cancer

Netherlands
Erasmus Medical Center

Recruiting

Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC (HAMLET)

Non-small Cell Lung Cancer

Netherlands
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
Merck KGaA, Darmstadt, Germany

Completed

EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)

Lung Cancer | Non Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease

Non-small Cell Lung Cancer

Netherlands
Academisch Ziekenhuis Maastricht
The Netherlands Cancer Institute; ZonMw: The Netherlands Organisation for Health...

Completed

Pharmacokinetic Boosting of Osimertinib (OSIBOOST)

Non Small Cell Lung Cancer

Netherlands
University Medical Center Groningen

Recruiting

Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer (VULCAN)

Non Small Cell Lung Cancer Metastatic

Netherlands
Maastricht Radiation Oncology
Anticancer Fund, Belgium; Reliable Cancer Therapies

Terminated

Nitroglycerin in Non-small Cell Lung Cancer (Nitroglycerin)

Non Small Cell Lung Cancer (NSCLC)

Netherlands
Radboud University Medical Center

Completed

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

NSCLC | Locally Advanced Non-Small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Stage IV (Oligo-metastases)

Netherlands
Maastricht University Medical Center

Recruiting

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat (OSIBOOST-2)

Non-small Cell Lung Cancer

Netherlands
Dutch Society of Physicians for Pulmonology and...

Completed

Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer (NVALT12)

Non Small Cell Lung Cancer

Netherlands
Erasmus Medical Center

Recruiting

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) (START-TKI)

Non Small Cell Lung Cancer | Liquid Biopsy | Tyrosine Kinase Inhibitor

Netherlands

Clinical Trials on Non Small Cell Lung Cancer (Squamous or Non Squamous) in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations